Steering Through Setbacks with AVEO Oncology's Michael Bailey 

For all the drug commercialization successes he's played a leading hand in during his tenures at GSK, Genentech, and ImClone-Androderm, Augmentin, necitumumab, and Erbitux among them-Michael Bailey concedes that he's likely better known for his failures. After hearing his stories on this episode of the Business of Biotech, I tend to disagree. While he offers a transparent and instructive look at the failures themselves, I'd contend it's what he's done with those setbacks that defines his biopharma and biotech leadership legacy. Today, Bailey is CEO at Aveo Oncology, a company that saw its own set of challenges during the clinical development of now-commercial FOTIVDA (tivozanib) and ficlatuzumab. Tune in for Bailey's straight-shooting insight on how to turn biotech setbacks on their ear.
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple...
Spotify - open.spotify.c...
RU-vid - • The Business Of Biotec...